Hematological Malignancies

Conclusions – Role of RIT in Follicular lymphoma • RIT simple and effective treatment; most active drug in NHL, unique mechanism of action – Effective (high response rate, durable remission) and underused single treatment in relapsed and rituximab refractory disease – Patients in 90 Y-ibritumomab arm had a greater than 5-year advantage in time to next treatment in FIT trial as consolidation – Phase II data as single agents Zevalin RIT in untreated follicular lymphoma show high response rates and durable remission – Novel Radioimmunconjugates are being developed but pathways to registration and routine clinical use are challenging.